About CASI Pharmaceuticals
CASI Pharmaceuticals (NASDAQ:CASI) is focused on developing and commercializing innovative therapeutics and pharmaceutical products, primarily for the treatment of cancer and other life-threatening diseases. The company is traded on the NASDAQ stock exchange under the ticker symbol CASI. With a commitment to improving patient outcomes, CASI Pharmaceuticals has a diverse portfolio of products in various stages of development, from research and pre-clinical trials to late-stage clinical trials. Their operations encompass a wide range of activities, including drug discovery, development, manufacturing, and commercialization, with the objective to bring new and effective treatments to market. The company collaborates with partners globally to leverage cutting-edge science in pursuit of breakthrough treatments.
Snapshot
Operations
Products and/or services of CASI Pharmaceuticals
- EVOMELA (melphalan) for conditioning treatment prior to stem cell transplantation in patients with multiple myeloma.
- CNCT19, a CD19 CAR-T cell therapy for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- CID-103, an anti-CD38 monoclonal antibody in development for multiple myeloma treatment.
- BI-1206, a monoclonal antibody designed to enhance the efficacy of anti-PD1 therapy in solid tumors.
CASI Pharmaceuticals executive team
- Dr. Alexander A. Zukiwski M.D.Executive VP & Chief Medical Officer
- Dr. Wei Zhang Ph.D.Senior Vice President
- Mr. David A. Cory M.B.A., R.Ph.CEO & Director
- Ms. Kun QianVP & Global Controller
- Ms. Chunhua WangChief Operating Officer
- Ms. Wei GaoGeneral Counsel
- Dr. Ingrid C. Choong Ph.D.Head of Corporate Development
- Dr. James E. Goldschmidt Ph.D.Chief Business Officer
- Mr. Hai HuangChief Commercial Officer & GM
- Dr. Junping ChenChief Medical Officer of China